Table 3.
On-going CAR-NK Clinical Trials.
| NCT Number | Title | Status | Conditions | Source of NK Cells | Interventions | Clinical trial phase | Population | Sponsor/ Collaborators | Locations | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04324996 | A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19 | Recruiting | • COVID-19 | Cord blood :NKG2D CAR- NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells | • Biological: NK cells,IL15-NK cells,NKG2D CAR- NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells | Study Type: Interventional Phase: • Phase 1 • Phase 2 |
Enrollment: 90 Age: 18 Years and older (Adult, Older Adult) Sex: ll |
• Chongqing Public Health Medical Center • Chongqing Sidemu Biotech • Zhejiang Qixin Biotech |
• Chongqing Public Health Medical Center, Chongqing, China |
| 2 | NCT03940833 | Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM Study Documents: | Recruiting | • Multiple Myeloma | Engineered NK-92 Cells | • Biological: BCMA CAR-NK 92 cells | Study Type: Interventional Phase: • Phase 1 • Phase 2 |
Enrollment: 20 Age: 18 Years to 80 Years (Adult, Older Adult) Sex: All |
• Asclepius Technology Company Group (Suzhou) Co., Ltd. | • Department of Hematology, Wuxi People's Hospital, Nanjing Medical University, Wuxi, Jiangsu, China |
| 3 | NCT03940820 | Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors Study Documents: | Recruiting | • Solid Tumor | ROBO1 Specific CAR-NK Cells | • Biological: ROBO1 CAR-NK cells | Study Type: Interventional Phase: • Phase 1 • Phase 2 |
Enrollment: 20 Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All |
• Asclepius Technology Company Group (Suzhou) Co., Ltd. | • Radiation Therapy Department, Suzhou Cancer Center, Suzhou Hospital Affiliated to Nanjing Medical University, Suzhou, Jiangsu, China |
| 4 | NCT04887012 | Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/ Relapsed B-cell NHL Study Documents: |
Recruiting | • B-cell Non Hodgkin Lymphoma | HLA haploidentical CAR-NK cells targeting CD19 | • Biological: anti- CD19 CAR-NK | Study Type: Interventional Phase: Phase 1 |
Enrollment: 25 Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All |
• Second Affiliated Hospital, School of Medicine, Zhejiang University | • 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China |
| 5 | NCT05020678 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers Study Documents: |
Recruiting | • Lymphoma, Non- Hodgkin • B-cell Acute Lymphoblastic Leukemia • Large B-cell Lymphoma • Mantle Cell Lymphoma |
allogeneic CAR NK cells targeting CD19 | • Biological: NKX019 | Study Type: Interventional Phase: Phase 1 |
Enrollment: 60 Age: 18 Years and older (Adult, Older Adult) Sex: All |
• Nkarta Inc. | • Colorado Blood Cancer Institute, Denver, Colorado, United States • Peter MacCallum Cancer Center, Melbourne, Victoria, Australia |